17-Apr-2024
No headlines found.
Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Globe Newswire (Wed, 3-Apr 8:00 AM ET)
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, "VOQUEZNA Can Kick Some Acid"
Globe Newswire (Tue, 26-Mar 8:00 AM ET)
Globe Newswire (Thu, 7-Mar 8:00 AM ET)
Globe Newswire (Thu, 29-Feb 8:00 AM ET)
Globe Newswire (Tue, 13-Feb 8:00 AM ET)
Globe Newswire (Wed, 31-Jan 8:00 AM ET)
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Phathom Pharmaceuticals trades on the NASDAQ stock market under the symbol PHAT.
As of April 17, 2024, PHAT stock price declined to $9.80 with 414,089 million shares trading.
PHAT has a beta of 1.28, meaning it tends to be more sensitive to market movements. PHAT has a correlation of 0.04 to the broad based SPY ETF.
PHAT has a market cap of $573.08 million. This is considered a Small Cap stock.
Last quarter Phathom Pharmaceuticals reported $682,000 in Revenue and -$1.39 earnings per share. This beat revenue expectation by $272,000 and missed earnings estimates by -$.31.
In the last 3 years, PHAT stock traded as high as $40.90 and as low as $5.84.
The top ETF exchange traded funds that PHAT belongs to (by Net Assets): VTI, IWM, VXF, IWN, IBB.
PHAT stock has underperformed the market in the last year with a return of -1.8%, while SPY returned +23.0%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in PHAT shares. However, PHAT has outperformed the market in the last 3 month and 2 week periods, returning +30.5% and 0.0%, while SPY returned +5.7% and -3.5%, respectively. This indicates PHAT has been having a stronger performance recently.
PHAT support price is $9.42 and resistance is $10.64 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PHAT stock will trade within this expected range on the day.